Dive into January’s Topics
Translational Drug Development (TD2)
The Precision Oncology CRO
Welcome to the January Edition of TD2's Monthly Newsletter. As we begin 2024, our focus on advancing cancer research remains unwavering. This issue features a selection of recent blogs, scientific posters, and videos, and highlights our key services. Our objective is to contribute significantly to oncology research and the development of new therapies. Stay updated with our latest research and insights.
E-BOOK
Using the Diet Induced Obese Mouse Model for Modern Cancer Research
Obesity, a known risk factor for several cancers, is often overlooked in cancer research that relies on outdated healthy mouse models. The Diet-Induced Obesity (DIO) mouse model addresses this by simulating the health profile of modern patients, including prevalent conditions like obesity and diabetes. This strategy, outlined in the playbook, seeks to improve the relevance and efficacy of cancer drug trials by more accurately representing current patient conditions.
FEATURED BLOG
Advancing Preclinical Cancer Research Through Metabolomics: Key Strategies for Biomarker Identification and Drug-Target Analysis in Immuno-Oncology
Learn about the impact of metabolomics in preclinical cancer research, highlighting its critical role in identifying biomarkers and mapping drug targets in immuno-oncology. It delves into how this approach enhances our understanding of cancer metabolism, aiding in the development of personalized, effective cancer therapies.
SERVICE SPOTLIGHT
Fully Characterized Syngeneic Models
Syngeneic models are essential for cancer research as they provide a highly relevant system to study tumor-immune interactions within a genetically identical background. TD2’s collection of fully characterized syngeneic models allow for the investigation of the immune system's response to cancer and the efficacy of immunotherapies.
Translational Oncology Services
Learn more about TD2's Clinical Trial Management and Regulatory Support Services here .